We are a committed team of visionary founders and experienced advisors supporting the mission of bringing our superior computer-based diagnostic tool for Alzheimer´s disease to the clinical market.
Brainreader has developed a cost-effective and easy to use technology that can analyse MRI images. The Neuroreader™ software enables accurate detection of atrophy in brain structures in early stages of Alzheimer´s disease.
The standardized and automated features of Neuroreader™ improves clinicians ability to assess brain atrophy correctly. Neuroreader™ hereby enables clinicians' to be more confident in their Alzheimer´s disease diagnosis. Press this link to test Neuroreader at your clinic.
03.07.2014 – Brainreader is proud to announce that the quality system of the company fulfills the requirements in EN ISO 13485:2012 and ISO 13485:2003 and therefore has been certified today.
It is our vision that ultimately Brainreader will enable a more targeted and efficient treatment of Alzheimer´s disease, which will increase the patients quality of life, increase the professional satisfaction of the clinician and significantly reduce disease-related costs for society. - Daniel Langhoff, CEO Brainreader